DNA methylation-mediated high expression of CCDC50 correlates with poor prognosis and hepatocellular carcinoma progression.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
07 08 2023
Historique:
received: 21 05 2023
accepted: 06 07 2023
medline: 22 8 2023
pubmed: 8 8 2023
entrez: 8 8 2023
Statut: ppublish

Résumé

Hepatocellular carcinoma (HCC) is one of the most common and lethal cancer types worldwide. Recent studies found Coiled-coil domain-containing protein 50 (CCDC50) could regulate the nuclear factor kappa-B and p53 signalling pathways in cancer. Nevertheless, the underlying biological function and potential mechanisms of CCDC50 driving the progression of HCC remain unclear. In this study, we found that CCDC50 was up-regulated in HCC, and its higher expression was associated with adverse clinical outcomes and poor clinical characteristics. The results of the Cox regression analysis revealed that CCDC50 was an independent factor for the prognosis of HCC. Meanwhile, we also established a nomogram based on CCDC50 to predict the 1-, 3-, or 5-year survival in HCC patients. Furthermore, we found that DNA hypomethylation results in its overexpression in HCC. In addition, functional annotation confirmed that CCDC50 was mainly involved in the neuroactive ligand-receptor interaction and protein digestion and absorption. Importantly, we found that CCDC50 was highly expressed in HCC cell lines. Depletion of CCDC50 significantly inhibits HCC cell proliferation and migration abilities. This is the first study to identify CCDC50 as a new potential prognostic biomarker and characterize the functional roles of CCDC50 in the progression of HCC, and provides a novel potential diagnostic and therapeutic biomarker for HCC in the future.

Identifiants

pubmed: 37552104
pii: 204899
doi: 10.18632/aging.204899
pmc: PMC10457044
doi:

Substances chimiques

CCDC50 protein, human 0
Intracellular Signaling Peptides and Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7424-7439

Références

Brief Bioinform. 2023 Jan 19;24(1):
pubmed: 36549921
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Front Oncol. 2022 Sep 28;12:937716
pubmed: 36248995
BMC Med Genomics. 2009 Apr 24;2:18
pubmed: 19393097
Gene. 2003 Sep 18;314:113-20
pubmed: 14527723
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
Cell Host Microbe. 2021 Feb 10;29(2):281-298.e5
pubmed: 33382980
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Mol Cancer. 2019 Dec 5;18(1):177
pubmed: 31805946
Biochim Biophys Acta. 2008 May;1783(5):826-37
pubmed: 18029035
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188314
pubmed: 31682895
Oncol Lett. 2020 Jun;19(6):4011-4023
pubmed: 32391104
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
Cell. 2013 Aug 29;154(5):1151-1161
pubmed: 23993102
Eur J Gastroenterol Hepatol. 2015 Aug;27(8):933-40
pubmed: 25933127
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cell Res. 2021 Jan;31(1):62-79
pubmed: 32612200
Hepatology. 2019 Jan;69(1):179-195
pubmed: 30028541
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Gastroenterology. 2017 Sep;153(3):812-826
pubmed: 28624577
J Exp Clin Cancer Res. 2020 Jun 19;39(1):116
pubmed: 32560659
Cell Mol Life Sci. 2022 Oct 29;79(11):572
pubmed: 36308630
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Front Mol Biosci. 2022 Feb 03;8:799497
pubmed: 35187070
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Nat Commun. 2022 May 4;13(1):2436
pubmed: 35508466
Leukemia. 2009 Nov;23(11):2018-26
pubmed: 19641524
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123

Auteurs

Chunhong Li (C)

Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.

Yingdong Jia (Y)

Gastrointestinal Surgical Unit, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.

Na Li (N)

Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.

Qiang Zhou (Q)

Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.

Rui Liu (R)

Department of Radiation Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.

Qiang Wang (Q)

Gastrointestinal Surgical Unit, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH